GPR30: a novel indicator of poor survival for endometrial carcinoma
Objective This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal g...
Gespeichert in:
| Veröffentlicht in: | American journal of obstetrics and gynecology 2007-04, Vol.196 (4), p.386.e1-386.e11 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 386.e11 |
|---|---|
| container_issue | 4 |
| container_start_page | 386.e1 |
| container_title | American journal of obstetrics and gynecology |
| container_volume | 196 |
| creator | Smith, Harriet O., MD Leslie, Kimberly K., MD Singh, Meenakshi, MD Qualls, Clifford R., PhD Revankar, Chetana M., PhD Joste, Nancy E., MD Prossnitz, Eric R., PhD |
| description | Objective This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results GPR30 correlated positively with epidermal growth factor receptor ( P = .005), but negatively with progesterone ( P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates. |
| doi_str_mv | 10.1016/j.ajog.2007.01.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70336029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002937807000051</els_id><sourcerecordid>70336029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-11f4dae169b0c9a2e8e3b0b9226ce41572c3ddab5babb22bba6b668a08959ef13</originalsourceid><addsrcrecordid>eNp9kUFr3DAQhUVoSTZJ_0AOxafe7IwkW7ZCKJSlSQqBhqQ9C0keB7m2tZXshfz7yuxCoYeeZh6892C-IeSKQkGBiuu-0L1_LRhAXQAtAMoTsqEg61w0onlHNgDAcsnr5oycx9ivkkl2Ss5oXQIvmdyQ7f3TM4ebTGeT3-OQual1Vs8-ZL7Ldj7NuIS92-sh65LAqfUjzsElbXWwbvKjviTvOz1E_HCcF-Tn3dcf24f88fv9t-2Xx9yWdTXnlHZlq5EKacBKzbBBbsBIxoTFklY1s7xttamMNoYxY7QwQjQaGllJ7Ci_IJ8Ovbvgfy8YZzW6aHEY9IR-iaoGzgUwmYzsYLTBxxiwU7vgRh3eFAW1olO9WtGpFZ0CqhK6FPp4bF_MiO3fyJFVMtweDJhu3DsMKlqHk8XWBbSzar37f__nf-J2cFOCPfzCN4y9X8KU6CmqIlOgXtZvrb-DOm1QUf4HsNuUBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70336029</pqid></control><display><type>article</type><title>GPR30: a novel indicator of poor survival for endometrial carcinoma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Smith, Harriet O., MD ; Leslie, Kimberly K., MD ; Singh, Meenakshi, MD ; Qualls, Clifford R., PhD ; Revankar, Chetana M., PhD ; Joste, Nancy E., MD ; Prossnitz, Eric R., PhD</creator><creatorcontrib>Smith, Harriet O., MD ; Leslie, Kimberly K., MD ; Singh, Meenakshi, MD ; Qualls, Clifford R., PhD ; Revankar, Chetana M., PhD ; Joste, Nancy E., MD ; Prossnitz, Eric R., PhD</creatorcontrib><description>Objective This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results GPR30 correlated positively with epidermal growth factor receptor ( P = .005), but negatively with progesterone ( P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.</description><identifier>ISSN: 0002-9378</identifier><identifier>EISSN: 1097-6868</identifier><identifier>DOI: 10.1016/j.ajog.2007.01.004</identifier><identifier>PMID: 17403429</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - analysis ; Biopsy, Needle ; Cohort Studies ; endometrial carcinoma ; Endometrial Neoplasms - genetics ; Endometrial Neoplasms - mortality ; Endometrial Neoplasms - pathology ; estrogen receptor ; Female ; GPR30 ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Staging ; Obstetrics and Gynecology ; Probability ; progesterone receptor ; Prognosis ; Receptors, Estrogen - biosynthesis ; Receptors, G-Protein-Coupled - biosynthesis ; Receptors, G-Protein-Coupled - genetics ; Receptors, G-Protein-Coupled - metabolism ; Risk Assessment ; Sensitivity and Specificity ; Statistics, Nonparametric ; survival ; Survival Analysis</subject><ispartof>American journal of obstetrics and gynecology, 2007-04, Vol.196 (4), p.386.e1-386.e11</ispartof><rights>Mosby, Inc.</rights><rights>2007 Mosby, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-11f4dae169b0c9a2e8e3b0b9226ce41572c3ddab5babb22bba6b668a08959ef13</citedby><cites>FETCH-LOGICAL-c475t-11f4dae169b0c9a2e8e3b0b9226ce41572c3ddab5babb22bba6b668a08959ef13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajog.2007.01.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17403429$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Harriet O., MD</creatorcontrib><creatorcontrib>Leslie, Kimberly K., MD</creatorcontrib><creatorcontrib>Singh, Meenakshi, MD</creatorcontrib><creatorcontrib>Qualls, Clifford R., PhD</creatorcontrib><creatorcontrib>Revankar, Chetana M., PhD</creatorcontrib><creatorcontrib>Joste, Nancy E., MD</creatorcontrib><creatorcontrib>Prossnitz, Eric R., PhD</creatorcontrib><title>GPR30: a novel indicator of poor survival for endometrial carcinoma</title><title>American journal of obstetrics and gynecology</title><addtitle>Am J Obstet Gynecol</addtitle><description>Objective This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results GPR30 correlated positively with epidermal growth factor receptor ( P = .005), but negatively with progesterone ( P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biopsy, Needle</subject><subject>Cohort Studies</subject><subject>endometrial carcinoma</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Endometrial Neoplasms - pathology</subject><subject>estrogen receptor</subject><subject>Female</subject><subject>GPR30</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Probability</subject><subject>progesterone receptor</subject><subject>Prognosis</subject><subject>Receptors, Estrogen - biosynthesis</subject><subject>Receptors, G-Protein-Coupled - biosynthesis</subject><subject>Receptors, G-Protein-Coupled - genetics</subject><subject>Receptors, G-Protein-Coupled - metabolism</subject><subject>Risk Assessment</subject><subject>Sensitivity and Specificity</subject><subject>Statistics, Nonparametric</subject><subject>survival</subject><subject>Survival Analysis</subject><issn>0002-9378</issn><issn>1097-6868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFr3DAQhUVoSTZJ_0AOxafe7IwkW7ZCKJSlSQqBhqQ9C0keB7m2tZXshfz7yuxCoYeeZh6892C-IeSKQkGBiuu-0L1_LRhAXQAtAMoTsqEg61w0onlHNgDAcsnr5oycx9ivkkl2Ss5oXQIvmdyQ7f3TM4ebTGeT3-OQual1Vs8-ZL7Ldj7NuIS92-sh65LAqfUjzsElbXWwbvKjviTvOz1E_HCcF-Tn3dcf24f88fv9t-2Xx9yWdTXnlHZlq5EKacBKzbBBbsBIxoTFklY1s7xttamMNoYxY7QwQjQaGllJ7Ci_IJ8Ovbvgfy8YZzW6aHEY9IR-iaoGzgUwmYzsYLTBxxiwU7vgRh3eFAW1olO9WtGpFZ0CqhK6FPp4bF_MiO3fyJFVMtweDJhu3DsMKlqHk8XWBbSzar37f__nf-J2cFOCPfzCN4y9X8KU6CmqIlOgXtZvrb-DOm1QUf4HsNuUBg</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>Smith, Harriet O., MD</creator><creator>Leslie, Kimberly K., MD</creator><creator>Singh, Meenakshi, MD</creator><creator>Qualls, Clifford R., PhD</creator><creator>Revankar, Chetana M., PhD</creator><creator>Joste, Nancy E., MD</creator><creator>Prossnitz, Eric R., PhD</creator><general>Mosby, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070401</creationdate><title>GPR30: a novel indicator of poor survival for endometrial carcinoma</title><author>Smith, Harriet O., MD ; Leslie, Kimberly K., MD ; Singh, Meenakshi, MD ; Qualls, Clifford R., PhD ; Revankar, Chetana M., PhD ; Joste, Nancy E., MD ; Prossnitz, Eric R., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-11f4dae169b0c9a2e8e3b0b9226ce41572c3ddab5babb22bba6b668a08959ef13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biopsy, Needle</topic><topic>Cohort Studies</topic><topic>endometrial carcinoma</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Endometrial Neoplasms - pathology</topic><topic>estrogen receptor</topic><topic>Female</topic><topic>GPR30</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Probability</topic><topic>progesterone receptor</topic><topic>Prognosis</topic><topic>Receptors, Estrogen - biosynthesis</topic><topic>Receptors, G-Protein-Coupled - biosynthesis</topic><topic>Receptors, G-Protein-Coupled - genetics</topic><topic>Receptors, G-Protein-Coupled - metabolism</topic><topic>Risk Assessment</topic><topic>Sensitivity and Specificity</topic><topic>Statistics, Nonparametric</topic><topic>survival</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Harriet O., MD</creatorcontrib><creatorcontrib>Leslie, Kimberly K., MD</creatorcontrib><creatorcontrib>Singh, Meenakshi, MD</creatorcontrib><creatorcontrib>Qualls, Clifford R., PhD</creatorcontrib><creatorcontrib>Revankar, Chetana M., PhD</creatorcontrib><creatorcontrib>Joste, Nancy E., MD</creatorcontrib><creatorcontrib>Prossnitz, Eric R., PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of obstetrics and gynecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Harriet O., MD</au><au>Leslie, Kimberly K., MD</au><au>Singh, Meenakshi, MD</au><au>Qualls, Clifford R., PhD</au><au>Revankar, Chetana M., PhD</au><au>Joste, Nancy E., MD</au><au>Prossnitz, Eric R., PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GPR30: a novel indicator of poor survival for endometrial carcinoma</atitle><jtitle>American journal of obstetrics and gynecology</jtitle><addtitle>Am J Obstet Gynecol</addtitle><date>2007-04-01</date><risdate>2007</risdate><volume>196</volume><issue>4</issue><spage>386.e1</spage><epage>386.e11</epage><pages>386.e1-386.e11</pages><issn>0002-9378</issn><eissn>1097-6868</eissn><abstract>Objective This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results GPR30 correlated positively with epidermal growth factor receptor ( P = .005), but negatively with progesterone ( P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>17403429</pmid><doi>10.1016/j.ajog.2007.01.004</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9378 |
| ispartof | American journal of obstetrics and gynecology, 2007-04, Vol.196 (4), p.386.e1-386.e11 |
| issn | 0002-9378 1097-6868 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70336029 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Biomarkers, Tumor - analysis Biopsy, Needle Cohort Studies endometrial carcinoma Endometrial Neoplasms - genetics Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology estrogen receptor Female GPR30 Humans Immunohistochemistry Middle Aged Neoplasm Staging Obstetrics and Gynecology Probability progesterone receptor Prognosis Receptors, Estrogen - biosynthesis Receptors, G-Protein-Coupled - biosynthesis Receptors, G-Protein-Coupled - genetics Receptors, G-Protein-Coupled - metabolism Risk Assessment Sensitivity and Specificity Statistics, Nonparametric survival Survival Analysis |
| title | GPR30: a novel indicator of poor survival for endometrial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A41%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GPR30:%20a%20novel%20indicator%20of%20poor%20survival%20for%20endometrial%20carcinoma&rft.jtitle=American%20journal%20of%20obstetrics%20and%20gynecology&rft.au=Smith,%20Harriet%20O.,%20MD&rft.date=2007-04-01&rft.volume=196&rft.issue=4&rft.spage=386.e1&rft.epage=386.e11&rft.pages=386.e1-386.e11&rft.issn=0002-9378&rft.eissn=1097-6868&rft_id=info:doi/10.1016/j.ajog.2007.01.004&rft_dat=%3Cproquest_cross%3E70336029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70336029&rft_id=info:pmid/17403429&rft_els_id=1_s2_0_S0002937807000051&rfr_iscdi=true |